Oxford Nanopore Shares Jump on Strong 2025 Revenue Outlook and Growth Expectations

Shares in **Oxford Nanopore Technologies PLC** (LSE: ONT) climbed strongly on Monday after the UK‑based DNA sequencing company reported expectations of robust revenue growth for 2025, significantly boosting investor sentiment. The firm forecast that **full‑year revenue will grow around the top end of its previously guided range of 20–23% on a constant‑currency basis**, a stronger outlook than many analysts had anticipated. The rise in the share price followed a series of updates showing solid momentum in the company’s performance, including strong growth in interim results and broader uptake of its sequencing products across research and applied markets. Oxford Nanopore’s sequence technology, which includes portable and scalable devices like PromethION and MinION, continues to attract demand globally. Investors responded positively to the improved revenue trajectory, reflecting confidence that the business can maintain growth despite broader biotech sector challenges and funding uncertainties in key markets. Management has reiterated guidance for 2025 and reaffirmed its strategic progress toward increased adoption of long‑read sequencing technologies. #OxfordNanopore #RevenueGrowth #BiotechStocks #DNASequencing #SlimScan #GrowthStocks #CANSLIM